Cargando…
Targeting ganglioneuromas with mTOR inhibitors
We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a...
Autores principales: | Tao, Ting, Shi, Hui, Durbin, Adam D., Look, A. Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849689/ https://www.ncbi.nlm.nih.gov/pubmed/33553609 http://dx.doi.org/10.1080/23723556.2020.1856621 |
Ejemplares similares
-
Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020) -
Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017) -
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
por: Rathore, Richa, et al.
Publicado: (2021) -
Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition
por: Kim, Hyung L
Publicado: (2014) -
VEGF signaling, mTOR complexes, and the endoplasmic reticulum: Towards a role of metabolic sensing in the regulation of angiogenesis
por: Karali, Evdoxia, et al.
Publicado: (2014)